AIM-listed Amryt Pharma (LON: AMYT) has announced a major transactions which will significantly boost their presence in the market. The products treat rare and orphan diseases and makes Amryt one of the global leaders in this space.
We interviewed CEO Dr Joe Wiley, who discusses the deal in the video below.
Amryt Pharma, Video for investors
Amryt are listed on Londons AIM Stock exchange with the ticker LON: AMYT
Amryt Investor Videos